ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Galmed Pharmaceuticals Ltd

Galmed Pharmaceuticals Ltd (GLMD)

0.3463
0.0161
(4.88%)
Closed March 29 04:00PM
0.3393
-0.007
(-2.02%)
After Hours: 07:18PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
0.3393
Bid
0.3202
Ask
0.33
Volume
41,981
0.32 Day's Range 0.349
0.26 52 Week Range 7.80
Market Cap
Previous Close
0.3302
Open
0.349
Last Trade
5
@
0.3403
Last Trade Time
Financial Volume
$ 13,987
VWAP
0.33317
Average Volume (3m)
149,735
Shares Outstanding
1,680,000
Dividend Yield
-
PE Ratio
-0.03
Earnings Per Share (EPS)
-10.63
Revenue
-
Net Profit
-17.87M

About Galmed Pharmaceuticals Ltd

Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aram... Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Tel Aviv, Center, Isr
Founded
1970
Galmed Pharmaceuticals Ltd is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker GLMD. The last closing price for Galmed Pharmaceuticals was $0.33. Over the last year, Galmed Pharmaceuticals shares have traded in a share price range of $ 0.26 to $ 7.80.

Galmed Pharmaceuticals currently has 1,680,000 shares outstanding. The market capitalization of Galmed Pharmaceuticals is $588,000 . Galmed Pharmaceuticals has a price to earnings ratio (PE ratio) of -0.03.

GLMD Latest News

Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis

Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis PR Newswire TEL AVIV, Israel, March 15...

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

      CUSIP No: M47238122   SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549       SCHEDULE 13G   (Rule 13d-102)   INFORMATION TO...

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

      UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     SCHEDULE 13G   (Rule 13d-102)   INFORMATION TO BE INCLUDED IN...

Form POS AM - Post-Effective amendments for registration statement

  As filed with the Securities and Exchange Commission on November 22, 2023. Registration No. 333-272722        UNITED STATES SECURITIES AND EXCHANGE...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

      UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 6-K   Report of Foreign Private Issuer Pursuant to Rule 13a-16 or...

Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study

Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study PR Newswire TEL AVIV, Israel, Nov. 20, 2023 TEL AVIV, Israel, Nov. 20, 2023 /PRNewswire/...

Form POS AM - Post-Effective amendments for registration statement

  As filed with the Securities and Exchange Commission on November 1, 2023. Registration No. 333-272722        UNITED STATES SECURITIES AND EXCHANGE...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.034311.24590163930.3050.3490.302655170.31823587CS
4-0.073-17.70555420810.41230.42990.32400240.3211906CS
12-0.0907-21.09302325580.430.46880.31497350.3484419CS
26-0.2514-42.55967496190.59070.87490.261743750.38899663CS
52-6.1107-94.73953488376.457.80.262148132.19923076CS
156-51.4107-99.344347826151.7561.20.2616760618.81206226CS
260-122.0607-99.7227941176122.4140.550.2615172836.87618606CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AVTXAvalo Therapeutics Inc
$ 22.08
(364.84%)
31.9M
NXLNexalin Technologies Inc
$ 1.50
(92.31%)
11.67M
CEROCERo Therapeutics Holdings Inc
$ 3.112
(90.92%)
24.08M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
KYCHKeyarch Acquisition Corporation
$ 12.30
(75.58%)
196.62k
BOLDBoundless Bio Inc
 14.25
(-76.24%)
767.63k
PMECPrimech Holdings Ltd
$ 1.2999
(-66.50%)
8.28M
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.1816
(-44.45%)
21.92M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
NBSTWNewbury Street Acquisition Corporation
$ 0.042279
(-38.28%)
1.75k
NKLANikola Corporation
$ 1.035
(13.85%)
163.84M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
MARAMarathon Digital Holdings Inc
$ 22.56
(2.22%)
86.14M
AKANAkanda Corporation
$ 0.1166
(-29.29%)
80.34M

GLMD Discussion

View Posts
Awl416 Awl416 2 weeks ago
Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis
๐Ÿ‘๏ธ0
Monksdream Monksdream 5 months ago
GLMD new 52=week low
๐Ÿ‘๏ธ0
Monksdream Monksdream 6 months ago
GLMD new 52 week low
๐Ÿ‘๏ธ0
Monksdream Monksdream 6 months ago
GLMD new 52 week low
๐Ÿ‘๏ธ0
Monksdream Monksdream 6 months ago
GLMD new 52 week low
๐Ÿ‘๏ธ0
Monksdream Monksdream 7 months ago
GLMD new 52 week low
๐Ÿ‘๏ธ0
Monksdream Monksdream 7 months ago
GLMD new 52 low
๐Ÿ‘๏ธ0
Monksdream Monksdream 8 months ago
GLMD new 52 week low
๐Ÿ‘๏ธ0
surf1944 surf1944 9 months ago
https://stockcharts.com/h-sc/ui?s=glmd&p=D&yr=0&mn=6&dy=0&id=p38090673899

https://www.barchart.com/stocks/quotes/glmd/technical-chart?plot=CANDLE&volume=total&data=DO&density=ML&pricesOn=1&asPctChange=0&logscale=0&indicators=ACCUM;SMA(20);SMA(50);SMA(100);SMA(200);CHKMF(20)&sym=SYSX&grid=1&height=210&studyheight=100

https://www.barchart.com/stocks/quotes/glmd/opinion

https://finance.yahoo.com/quote/GLMD?p=GLMD

https://www.nasdaq.com/market-activity/spos

$1.25 offering
๐Ÿ‘๏ธ0
Triple nickle Triple nickle 9 months ago
Lol caught a falling knife
๐Ÿ‘๏ธ0
AJ Freely AJ Freely 9 months ago
$GLMD - ??Up 20% Pre-Market/ Current Price $2.91
To employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC
๐Ÿ‘๏ธ0
Awl416 Awl416 9 months ago
Woot woot
๐Ÿ‘๏ธ0
Golden Cross Golden Cross 11 months ago
Nice
๐Ÿ‘๏ธ0
HoldEm777 HoldEm777 11 months ago
https://www.prnewswire.com/news-releases/galmed-announces-initiation-of-a-clinical-development-program-to-evaluate-aramchol-meglumine-for-the-treatment-of-primary-sclerosing-cholangitis-psc-301819268.html
๐Ÿ‘๏ธ0
HoldEm777 HoldEm777 11 months ago
https://ih.advfn.com/stock-market/NASDAQ/galmed-pharmaceuticals-GLMD/historical
๐Ÿ‘๏ธ0
surf1944 surf1944 11 months ago
https://stockcharts.com/h-sc/ui?s=glmd&p=D&yr=0&mn=6&dy=0&id=p38090673899

https://www.barchart.com/stocks/quotes/glmd/technical-chart?plot=CANDLE&volume=total&data=DO&density=ML&pricesOn=1&asPctChange=0&logscale=0&indicators=ACCUM;SMA(20);SMA(50);SMA(100);SMA(200);CHKMF(20)&sym=SYSX&grid=1&height=210&studyheight=100

https://www.barchart.com/stocks/quotes/glmd/opinion

Open gap on the chart at .30
๐Ÿ‘๏ธ0
Golden Cross Golden Cross 11 months ago
$GLMD Galmed Pharmaceuticals forms a Strategic Partnership with OnKai

https://galmedpharma.investorroom.com/2023-05-04-Galmed-Pharmaceuticals-forms-a-Strategic-Partnership-with-OnKai
๐Ÿ‘๏ธ0
madras50 madras50 11 months ago
any idea what the deal is here?
๐Ÿ‘๏ธ0
SmokeSignals SmokeSignals 11 months ago
wow!
๐Ÿ‘๏ธ0
ZZZ888 ZZZ888 1 year ago
Wow no one posted anything on this move today shocker
๐Ÿ‘๏ธ0
now invest now invest 3 years ago
Decent move ..thus far today!! Like it!!
๐Ÿ‘๏ธ0
now invest now invest 3 years ago
Ah... news... starting dosing!!..
๐Ÿ‘๏ธ0
now invest now invest 3 years ago
Well.... guess it depends on definitions!! I see a 20-40 % gain in less than 4-6 months!! The more than 3x some are expecting.... will probably be longer!!
๐Ÿ‘๏ธ0
swagman swagman 3 years ago
I agree ... better to have strong institutional interest (as per recent activity after KOL event) than here but I think it'll still be a year or so before this stock really takes off
๐Ÿ‘๏ธ0
now invest now invest 3 years ago
Nice day again!! And no interest here!! HEY ok with me!! LOL
๐Ÿ‘๏ธ0
now invest now invest 3 years ago
Nice move today!! Nice volume also!!
๐Ÿ‘๏ธ0
Vader69 Vader69 3 years ago
Volume was up 3x normal yesterday on 12/15. The 100 day moving average was also breached suggestive of something cooking. Very exciting company; interesting to see where this goes
๐Ÿ‘๏ธ0
ClayTrader ClayTrader 4 years ago
* * $GLMD Video Chart 12-04-2019 * *

Link to Video - click here to watch the technical chart video

๐Ÿ‘๏ธ0
DewDiligence DewDiligence 5 years ago
GLMD phase-2b data NASH data:

https://finance.yahoo.com/news/phase-2-data-galmed-pharmaceuticals-163000034.html
๐Ÿ‘๏ธ0
DewDiligence DewDiligence 5 years ago
GLMD 3Q18 resultsโ€”cash=$92.3M:

https://finance.yahoo.com/news/galmed-pharmaceuticals-provides-business-reports-120000693.html
๐Ÿ‘๏ธ0
Amatuer17 Amatuer17 6 years ago
Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q2 2018 Results - Earnings Call Transcript $GLMD

https://seekingalpha.com/article/4194869

The final cost of the trial will be around $75 million
200 centers
Start by Q2-2019
Duration 52 weeks
No of patients - around 300

Study enrollment may take 12-18 months + 12 months + 3-4 months for topline results - we are looking at 32-36 months or 3 years - which is Q2-2022

If there is no buyout or partnership - we will see just dilution and SP going down
๐Ÿ‘๏ธ0
DewDiligence DewDiligence 6 years ago
GLMD 2Q18 CC notes re phase-3 NASH trial:

https://twitter.com/DewDiligence/status/1025045825884438530
๐Ÿ‘๏ธ0
DewDiligence DewDiligence 6 years ago
GLMD 2Q18 results:

https://finance.yahoo.com/news/galmed-pharmaceuticals-provides-business-reports-110000942.html

6/30/18 cash was $94.1M.
๐Ÿ‘๏ธ0
conix conix 6 years ago
GLMD chart

๐Ÿ‘๏ธ0
investor86 investor86 6 years ago
Thinking to put 20k in it for long run. Raitings are great.
๐Ÿ‘๏ธ0
crudeoil24 crudeoil24 6 years ago
Galmed Notches Second Bullish Rating On Aramchol Opportunity
10:49 am ET July 13, 2018 (Benzinga) Print
Two days after Cantor Fitzgerald gave Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) a shot in the arm with an ultrabullish rating, Stifel Nicolaus administered a booster.

Galmed spiked 15 percent Friday morning after already having risen 21 percent in the preceding session.

The Analyst

Stifel analyst Adam Walsh initiated coverage of Galmed with a Buy rating and $35 price target.

The Thesis

As with Cantor Fitzgerald, Galmedโ€™s Aramchol was again the point of optimism.

Walsh considers the candidate a multibillion-dollar opportunity for the treatment of non-alcoholic steatohepatitis, or NASH, and forecast a โ€œdecent chanceโ€ of an Aramchol partnership deal materializing ahead of the Phase 3 trial launch in the first half of 2019. (See Walsh's track record here.)

โ€œWe think large-pharma validation could drive shares significantly higher,โ€ the analyst said.

With positive Phase 2b results failing to stimulate the stock, Stifel said the Street overlooked Aramcholโ€™s strengths and thereby created a buying opportunity.

Aramchol did not reach statistical significance on either of two approvable endpoints โ€” but they were secondary endpoints and were not powered for statistics, Walsh said.

โ€œWhile Aramchol did not hit statistical significance on either of the two approvable endpoints, we remind investors that these โ€œDespite this, Aramchol nearly hit on NASH resolution without worsening of fibrosis and showed strong trends on the fibrosis improvement with no worsening of NASH.โ€

The analyst expects the next phase to generate the statistically significant data investors demand.

After conversations with management, Walsh rejected concerns over dropout rates and competition from Madrigal Pharmaceuticals Inc (NASDAQ: MDGL).

Price Action

Galmed shares were rallying 16.27 percent to $14.85 at the time of publication Friday morning.

Related Links:

Galmed Shares More Than Double As It Hits Bullseye With Fatty Liver Candidate

Zogenix Soars On Positive Phase 3 Data In Dravet Syndrome Study

Photo by Nephron/Wikimedia.

Latest Ratings for GLMD DateFirmActionFromTo

Jul 2018Stifel NicolausInitiates Coverage OnBuy Jul 2018Cantor FitzgeraldInitiates Coverage OnOverweight Jun 2018Maxim GroupMaintainsBuyBuy
๐Ÿ‘๏ธ0
crudeoil24 crudeoil24 6 years ago
15.39 > very bullish!
๐Ÿ‘๏ธ0
crudeoil24 crudeoil24 6 years ago
Heading back to $20.00+ very,very,soon!
๐Ÿ‘๏ธ0
crudeoil24 crudeoil24 6 years ago
Galmed Pharmaceuticals started at buy with $35 stock price target at Stifel Nicolaus
7:26 am ET July 13, 2018 (MarketWatch)
Share
Print
(END) Dow Jones Newswires

July 13, 2018 07:26 ET (11:26 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.
๐Ÿ‘๏ธ0
crudeoil24 crudeoil24 6 years ago
Price Target Announced at $59.00/Share by Cantor Fitzgerald

Ratings actions from Benzinga: http://www.benzinga.com/stock/GLMD/ratings

(END) Dow Jones Newswires

July 11, 2018 16:24 ET (20:24 GMT)
๐Ÿ‘๏ธ0
DewDiligence DewDiligence 6 years ago
GLMD sells 5.75M* shares @$15.00โ€”a 9% discount to last Fridayโ€™s close:

https://finance.yahoo.com/news/galmed-pharmaceuticals-ltd-announces-pricing-013700954.html

Net proceeds from the offering will be about $81M*.

*Assuming exercise of underwriterโ€™s option.
๐Ÿ‘๏ธ0
DewDiligence DewDiligence 6 years ago
GLMD updates patent information:

https://www.sec.gov/Archives/edgar/data/1595353/000114420418034494/tv496661_ex99-3.htm
๐Ÿ‘๏ธ0
DewDiligence DewDiligence 6 years ago
GLMD seeking $86.3M* on unspecified terms:

https://www.sec.gov/Archives/edgar/data/1595353/000114420418034494/tv496661_ex99-2.htm

A new corporate slide deck has been issued to accompany the above PR:
https://www.sec.gov/Archives/edgar/data/1595353/000114420418034494/tv496661_ex99-1.htm

*Assuming exercise of underwriterโ€™s option.
๐Ÿ‘๏ธ0
cjstocksup cjstocksup 6 years ago
Out at $21.20's. GL everyone.
๐Ÿ‘๏ธ0
dirtydozen911 dirtydozen911 6 years ago
shorted a handfull at $22...just got out when she dipped under $19...may go long later.....glta
๐Ÿ‘๏ธ0
cjstocksup cjstocksup 6 years ago
Back in here in the 19's and 20's for round 2 ahead. Todays run from pre market $10 to $12 to over $27.00 after the open was insane! Hope we do it again this afternoon. The float is gone now. Looks like the walkdown is buyers with tight stop losses on the drop;
๐Ÿ‘๏ธ0
Awl416 Awl416 6 years ago
I was waiting for your pal CJ to show up here
๐Ÿ‘๏ธ0
cjstocksup cjstocksup 6 years ago
Awesome pre market. Out here. GL everyone.
๐Ÿ‘๏ธ0
DewDiligence DewDiligence 6 years ago
GLMD PR on phase-2b ARREST study in NASH:

https://finance.yahoo.com/news/galmeds-600-mg-aramchol-achieved-110000752.html
๐Ÿ‘๏ธ0
crudeoil24 crudeoil24 6 years ago
Trading float is 10.6 million shares, according to MarketWatch.
๐Ÿ‘๏ธ0

Your Recent History

Delayed Upgrade Clock